EL NILE. - Keresési eredmények

novartis europharm limited - secukinumab - arthritis, psoriatic; psoriasis; spondylitis, ankylosing - immunszuppresszánsok - plaque psoriasiscosentyx is indicated for the treatment of moderate to severe plaque psoriasis in adults and children from the age of 6 years old who are candidates for systemic therapy. hidradenitis suppurativa (hs)cosentyx is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adults with an inadequate response to conventional systemic hs therapy. arthritis arthritiscosentyx, egyedül vagy kombinálva metotrexát (mtx), javasolt a kezelés aktív arthritis psoriaticában szenvedő felnőtt betegek esetében, ha a válasz, hogy korábbi betegség módosító anti reumás gyógyszer (adtak) terápia már nem megfelelő. axiális spondyloarthritis (axspa)bechterew-kór (mint, radiológiai axiális spondyloarthritis)cosentyx kezelésére javallt aktív bechterew-kór a felnőttek, akik reagáltak megfelelően a hagyományos terápia. non-radiographic axial spondyloarthritis (nr-axspa)cosentyx is indicated for the treatment of active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri) evidence in adults who have responded inadequately to non steroidal anti inflammatory drugs (nsaids). juvenile idiopathic arthritis (jia)enthesitis-related arthritis (era)cosentyx, alone or in combination with methotrexate (mtx), is indicated for the treatment of active enthesitis-related arthritis in patients 6 years and older whose disease has responded inadequately to, or who cannot tolerate, conventional therapy. juvenile psoriatic arthritis (jpsa)cosentyx, alone or in combination with methotrexate (mtx), is indicated for the treatment of active juvenile psoriatic arthritis in patients 6 years and older whose disease has responded inadequately to, or who cannot tolerate, conventional therapy.

Európai Unió - magyar - EMA (European Medicines Agency)

gardasil 9

merck sharp & dohme b.v. - humán papillomavírus vakcina [6, 11, 16, 18, 31, 33, 45, 52, 58] (rekombináns, adszorbeált) - condylomata acuminata; papillomavirus infections; immunization; uterine cervical dysplasia - papilloma vakcina - a gardasil 9 jelzi az aktív immunizálására a magánszemélyek éves kortól 9 éves ellen a következő hpv betegségek:premalignus elváltozások, rák érintő, a méhnyak, a szeméremtest, hüvely, végbél által okozott vakcina hpv-typesgenital szemölcsök (condyloma acuminata) által okozott specifikus hpv-típusok. lásd a 4. 4 és 5. 1 fontos információ az adatok, amelyek támogatják ezek a jelzések. a gardasil használatát 9 összhangban kell lennie a hivatalos ajánlások.

Európai Unió - magyar - EMA (European Medicines Agency)

amgevita

amgen europe b.v. - adalimumab - arthritis, psoriatic; colitis, ulcerative; arthritis, juvenile rheumatoid; spondylitis, ankylosing; psoriasis; crohn disease; arthritis, rheumatoid - immunszuppresszánsok - rheumatoid arthritis amgevita in combination with methotrexate, is indicated for: , the treatment of moderate to severe, active rheumatoid arthritis in adult patients when the response to disease-modifying anti-rheumatic drugs including methotrexate has been inadequate. a kezelés súlyos, aktív, mind a progresszív rheumatoid arthritisben szenvedő felnőttek korábban nem kezelt metotrexát. , amgevita can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate. amgevita csökkenti a progresszió mértéke az ízületi károsodás mérve x-ray, valamint javítja a fizikai funkció, amikor az adott metotrexát együtt. juvenile idiopathic arthritis polyarticular juvenile idiopathic arthritis amgevita in combination with methotrexate is indicated for the treatment of active polyarticular juvenile idiopathic arthritis, in patients from the age of 2 years who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (dmards). amgevita monoterápiaként intolerancia esetén, metotrexát, vagy ha a folyamatos metotrexát-kezelés nem megfelelő (a hatékonysági monoterápia lásd 5. adalimumab nem vizsgálták, hogy a betegek körében kevesebb, mint 2 év. enthesitis-related arthritis amgevita is indicated for the treatment of active enthesitis-related arthritis in patients, 6 years of age and older, who have had an inadequate response to, or who are intolerant of, conventional therapy (see section 5. axial spondyloarthritis ankylosing spondylitis (as) amgevita is indicated for the treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to conventional therapy. axial spondyloarthritis without radiographic evidence of as amgevita is indicated for the treatment of adults with severe axial spondyloarthritis without radiographic evidence of as but with objective signs of inflammation by elevated crp and/or mri, who have had an inadequate response to, or are intolerant to non-steroidal anti-inflammatory drugs. psoriatic arthritis amgevita is indicated for the treatment of active and progressive psoriatic arthritis in adults when the response to previous disease-modifying anti-rheumatic drug therapy has been inadequate. amgevita csökkenti a periferiás ízületi károsodás mérve x-ray a betegek polyarticularis szimmetrikus altípusai a betegség (lásd 5. 1) bekezdése, valamint javítja a fizikai funkció. psoriasis amgevita is indicated for the treatment of moderate to severe chronic plaque psoriasis in adult patients who are candidates for systemic therapy. paediatric plaque psoriasis amgevita is indicated for the treatment of severe chronic plaque psoriasis in children and adolescents from 4 years of age who have had an inadequate response to or are inappropriate candidates for topical therapy and phototherapies. hidradenitis suppurativa (hs) amgevita is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adults and adolescents from 12 years of age with an inadequate response to conventional systemic hs therapy (see sections 5. 1 5. crohn’s disease amgevita is indicated for treatment of moderately to severely active crohn’s disease, in adult patients who have not responded despite a full and adequate course of therapy with a corticosteroid and/or an immunosuppressant; or who are intolerant to or have medical contraindications for such therapies. paediatric crohn's disease amgevita is indicated for the treatment of moderately to severely active crohn's disease in paediatric patients (from 6 years of age) who have had an inadequate response to conventional therapy including primary nutrition therapy and a corticosteroid and/or an immunomodulator, or who are intolerant to or have contraindications for such therapies. ulcerative colitis amgevita is indicated for treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6-mercaptopurine (6-mp) or azathioprine (aza), or who are intolerant to or have medical contraindications for such therapies. uveitis amgevita is indicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients who have had an inadequate response to corticosteroids, in patients in need of corticosteroid-sparing, or in whom corticosteroid treatment is inappropriate. paediatric uveitis amgevita is indicated for the treatment of paediatric chronic non-infectious anterior uveitis in patients from 2 years of age who have had an inadequate response to or are intolerant to conventional therapy, or in whom conventional therapy is inappropriate.